ADMA BIOLOGICS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $510.2M | $426.5M | $258.2M | $154.1M | $80.9M |
| Cost of revenue | $217.4M | $206.9M | $169.3M | $118.8M | $79.8M |
| Gross profit | $292.8M | $219.6M | $88.9M | $35.3M | $1.2M |
| Selling, general & administrative | $91.6M | $74.1M | $59.0M | $52.5M | $42.9M |
| Research and development | $4.8M | $1.8M | $3.3M | $3.6M | $3.6M |
| Operating expenses | $101.3M | $80.6M | $67.3M | $74.6M | $59.5M |
| Operating income | $191.4M | $139.0M | $21.6M | -$39.4M | -$58.4M |
| Interest expense | $7.1M | $13.9M | $25.0M | $19.3M | $13.1M |
| Pretax income | $182.7M | $125.7M | -$28.2M | -$65.9M | — |
| Income tax expense | $35.7M | -$72.0M | $0 | $0 | $0 |
| Net income | $146.9M | $197.7M | -$28.2M | -$65.9M | -$71.6M |
| Balance Sheet | |||||
| Cash and equivalents | $87.6M | $103.1M | $51.4M | $86.5M | $51.1M |
| Current assets | $466.5M | $331.4M | $257.0M | $270.4M | $208.7M |
| Total assets | $624.2M | $488.7M | $329.2M | $348.5M | $276.3M |
| Current liabilities | $69.5M | $55.5M | $49.8M | $39.3M | $30.4M |
| Total liabilities | $146.9M | $139.7M | $194.0M | $196.5M | $135.1M |
| Stockholders' equity | $477.3M | $349.0M | $135.2M | $152.0M | $141.2M |
| Cash Flow Statement | |||||
| Cash from operations | $50.4M | $118.7M | $8.8M | -$59.5M | -$112.4M |
| Depreciation and amortization | $8.0M | $7.7M | $7.6M | $6.4M | $4.8M |
| Stock-based compensation | $20.0M | $13.6M | $6.2M | $5.2M | $3.5M |
| Capital expenditure | $22.6M | $8.2M | $4.8M | $13.9M | $13.5M |
| Free cash flow | $27.8M | $110.4M | $4.0M | -$73.4M | -$125.9M |
| Share repurchases | $31.9M | $0 | $0 | — | — |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 231.8M · Free float 90.7%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.